Matching articles for "Bydureon BCise"
Comparison Chart: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes (online only)
View the Comparison Chart: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes
Med Lett Drugs Ther. 2025 Nov 24; 67(1742):e195-6 doi:10.58347/tml.2025.1742c
View the Comparison Chart: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes
In Brief: New FDA Warning of Pulmonary Aspiration with GLP-1 Receptor Agonists
The package inserts of the GLP-1 receptor agonists dulaglutide (Trulicity) , exenatide (Byetta, Bydureon BCise) , liraglutide (Saxenda, Victoza) , and semaglutide (Ozempic, Rybelsus, Wegovy) and the dual…
Med Lett Drugs Ther. 2024 Dec 23; 66(1718):201-2 doi:10.58347/tml.2024.1718a
The package inserts of the GLP-1 receptor agonists dulaglutide (Trulicity) , exenatide (Byetta, Bydureon BCise) , liraglutide (Saxenda, Victoza) , and semaglutide (Ozempic, Rybelsus, Wegovy) and the dual glucosedependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) have been updated to include rare postmarketing reports of pulmonary aspiration associated with their use in patients undergoing elective surgery or other procedures requiring general anesthesia or deep sedation who had residual gastric contents despite preoperative fasting.
In Brief: GI Effects of GLP-1 Receptor Agonists
Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro) are widely prescribed for treatment of type 2…
Med Lett Drugs Ther. 2023 Nov 27; 65(1690):191-2 doi:10.58347/tml.2023.1690e
Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro) are widely prescribed for treatment of type 2 diabetes and weight management (see Table 1), but they delay gastric emptying and commonly cause nausea and vomiting. Gastroparesis and bowel obstruction (ileus) have also been reported with their use.
Empagliflozin (Jardiance) for Type 2 Diabetes in Children (online only)
The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin has been available for years alone ( Jardiance – Boehringer Ingelheim) and in combination with metformin (Synjardy) to improve glycemic…
Med Lett Drugs Ther. 2023 Aug 21; 65(1683):e137 doi:10.58347/tml.2023.1683e
The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin has been available for years alone ( Jardiance – Boehringer Ingelheim) and in combination with metformin (Synjardy) to improve glycemic control in adults with type 2 diabetes. Both products have now been approved for use in children ≥10 years old. Empagliflozin is the second oral drug to become available in the US for treatment of type 2 diabetes in children; metformin has been available since 2000 for this indication. The injectable glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide (Victoza) and extended-release exenatide (Bydureon BCise) are also approved for use in children ≥10 years old.
